Pharmacology of clovoxamine, a new non-tricyclic antidepressant.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002319:Cardiovascular System / Q000187:drug effects; D004285:Dogs; D004357:Drug Synergism; D004987:Ethers / Q000494:pharmacology; D006168:Guinea Pigs; D051379:Mice; D008996:Monoamine Oxidase Inhibitors; D009638:Norepinephrine / Q000378:metabolism / Q000494:pharmacology; D010091:Oximes / Q000494:pharmacology*; D010275:Parasympathetic Nervous System / Q000187:drug effects; D010293:Pargyline / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism / Q000494:pharmacology; D013747:Tetrabenazine / Q000037:antagonists & inhibitors
D000928:Antidepressive Agents; D004987:Ethers; D008996:Monoamine Oxidase Inhibitors; D010091:Oximes; D012701:Serotonin; D010293:Pargyline; D009638:Norepinephrine; D013747:Tetrabenazine